A new breakthrough in Parkinson’s disease treatment is set to revolutionize the lives of patients as the NHS prepares to offer a 24-hour wearable drug pump. This innovative technology is expected to provide round-the-clock medication to patients suffering from advanced Parkinson’s disease, eliminating the need for multiple daily tablets.

The wearable pump, which administers an infusion known as foslevodopa-foscarbidopa through a cannula under the skin, is controlled by a small automatic pump worn by patients at all times. The infusion works by converting the drug foslevodopa into dopamine, a neurotransmitter that plays a crucial role in motor function and movement control.

Dr. Katherine Fletcher from Parkinson’s UK explained the mechanism of the pump and highlighted its potential to transform the lives of patients who are no longer responsive to oral medication. The introduction of this technology has been described as ‘great news’ by James Palmer, NHS England’s medical director for specialised services, particularly for those struggling with the debilitating effects of Parkinson’s disease.

The therapy is expected to offer a new treatment option for nearly a thousand patients who are not suitable for other existing treatments, such as deep brain stimulation. This development is anticipated to significantly improve the quality of life for individuals living with Parkinson’s disease, which currently affects approximately 153,000 people in the UK.

John Whipps, a participant in the clinical trial for the pump, expressed how the new technology has empowered him to regain control over his life. Having previously relied on nearly 20 tablets a day to manage his symptoms, he emphasized the positive impact of the wearable pump on his ability to plan and engage in daily activities.